Sigilon Therapeutics, Inc.: Nasdaq/NYSE listing notice — Sigilon Therapeutics receives Nasdaq delisting notice for bid price non-compliance; will request hearing

Sigilon Therapeutics, Inc.

Nasdaq notified Sigilon on Dec 20, 2022 that its common stock will be delisted from the Nasdaq Global Select Market.
Delisting stems from failure to maintain minimum $1.00 bid price after 180-day grace period ended Dec 19, 2022.
Company intends to timely request a hearing before the Nasdaq Hearings Panel, which will stay delisting pending decision.
No assurance that the Panel will grant continued listing or that Sigilon can regain compliance within any granted period.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Sigilon Therapeutics, Inc. received a nasdaq delisting notice notice regarding minimum bid price (rules 5450(a)(1)).

Exchange: nasdaq
Notice: delisting notice
Deficiency: minimum bid price
Rules: 5450(a)(1)

Exact text from the filing

December 20, 2022, the Company received notice from the Staff indicating that the Staff had determined to delist the Company’s securities from The Nasdaq Global Select Market based upon the Company’s continued non-compliance with the $1.00 bid price requirement unless the Company timely requests a hearing before the Nasdaq Hearings Panel (the “Panel”). The Company intends to timely request a hearing before the Panel, which request will stay any further action by the Staff pending the Panel’s decision. The hearing request submitted by the Company would also stay the suspension of securities unt

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0001558370-22-018890

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.